Breast-Feeding, Other Factors, May Affect Risk of Breast Cancer Type

Publication
Article
OncologyONCOLOGY Vol 22 No 10
Volume 22
Issue 10

Factors such as age at menopause and a woman’s breast-feeding practices can influence her risk of developing certain types of breast cancer. That was the conclusion of a new study to be published in the October 1, 2008, issue of CANCER. The study’s results suggest that there are distinct and separate hormonal risk factors associated with different subtypes of breast cancer.

Factors such as age at menopause and a woman’s breast-feeding practices can influence her risk of developing certain types of breast cancer. That was the conclusion of a new study to be published in the October 1, 2008, issue of CANCER. The study’s results suggest that there are distinct and separate hormonal risk factors associated with different subtypes of breast cancer.

Amanda Phipps, a predoctoral research associate at the Fred Hutchinson Cancer Research Center in Seattle, and her colleagues conducted a study to better understand the specific risk factors for the subtypes of breast cancer, which are classified by expression of the estrogen receptor, the progesterone receptor, and the HER2 receptor. The research team suspected that reproductive or hormonal factors may play a significant role in a woman’s risk of developing different subtypes because these cell receptors are influenced by endogenous sex hormones.

The scientists pooled two population-based studies of breast cancer in women aged 55 to 79 years. Their analysis included 1,023 women with breast cancer whose cells express the estrogen and progesterone receptors (luminal cancers), 39 women with HER2-overexpressing breast cancer, and 78 triple-negative cases (no expression of estrogen, progesterone, or HER2 receptors). The study also included 1,476 women without breast cancer.

Risk Factors Varied by Subtype

The investigators found that reproductive risk factors varied considerably by breast cancer subtype. For example, early age at menarche was associated with risk of HER2-overexpressing disease but not with any other subtype. Breast-feeding for 6 months or longer was associated with a lower risk of luminal cancer as well as triple-negative cancer. Both late age at menopause and use of estrogen plus progestin hormonal therapy were associated with an increased risk of luminal disease. Finally, no differences in risks associated with number of children or the age when a woman first gave birth were observed by subtype.

The study authors concluded that their results indicate that “certain reproductive factors may have a greater impact on risk of certain molecular subtypes of disease compared to others.”

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Related Content